Investing.com - Financial Markets Worldwide

UPDATE 1-Philippines to buy 20 million Moderna vaccine doses as COVID-19 cases rise

Published 01/19/2021, 07:38 PM
Updated 01/19/2021, 07:40 PM
© Reuters
AZN
-
NVAX
-
SVA
-
MRNA
-

* Moderna to supply more than 20 million doses of vaccine
* Two Chinese firms allowed to hold Phase 3 clinical trials
* Duterte to be privately inoculated with Sinovac vaccine

(Adds details on clinical trial approvals, background)
MANILA, Jan 19 (Reuters) - The Philippines will buy 20
million doses of Moderna's MRNA.O COVID-19 vaccine,
presidential spokesman Harry Roque said on Tuesday, adding to
deals for a total of 72 million doses from AstraZeneca AZN.L ,
Novavax NVAX.O and Sinovac SVA.O .
With more than 504,000 COVID-19 cases and nearly 10,000
deaths, as of Tuesday, the Philippines has the second highest
level of infections in Southeast Asia.
President Rodrigo Duterte has said he preferred that the
Philippines sources its COVID-19 vaccines from either China or
Russia and on Tuesday Food and Drug Administration chief Rolando
Enrique Domingo told state-owned PTV network that late-stage
clinical trial applications from Sinovac and Clover
Biopharmaceuticals have been approved. Duterte wants to take the Sinovac vaccine as soon as it is
available, but without media coverage of the vaccination, Roque
told a regular news conference.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.